Nippon Shinyaku Co Ltd 2024 IR
The report highlights Nippon Shinyaku's financial and non-financial performance for fiscal year 2023, achieving record-high revenue of 148,255 million yen and operating profit of 33,295 million yen. The company launched its 7th Five-Year Medium-Term Management Plan to drive global growth beyond the patent cliff of its key drug, Uptravi. Key sustainability achievements include a 20.7% reduction in Scope 1 and 2 CO2 emissions and obtaining SBTi approval for its greenhouse gas reduction targets. Additionally, the company completed the construction of its nucleic acid API purification plant at the Odawara Central Factory to strengthen its global supply chain.
Company: Nippon Shinyaku Co Ltd
Sector: Health Care
Country: Japan
Year: 2024
Type: IR
Pages: 47
Nippon Shinyaku Co Ltd
Integrated Report
The report highlights Nippon Shinyaku's financial and non-financial performance for fiscal year 2023, achieving record-high revenue of 148,255 million yen and operating profit of 33,295 million yen. The company launched its 7th Five-Year Medium-Term Management Plan to drive global growth beyond the patent cliff of its key drug, Uptravi. Key sustainability achievements include a 20.7% reduction in Scope 1 and 2 CO2 emissions and obtaining SBTi approval for its greenhouse gas reduction targets. Additionally, the company completed the construction of its nucleic acid API purification plant at the Odawara Central Factory to strengthen its global supply chain.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2024
Reporting Period
Apr 1, 2023 - Mar 31, 2024
Fiscal Year
2023
Type
Integrated Report
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
Assurance
Assurance Standard
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Scope 3:
Energy Consumption
Renewable Energy
Water Consumption
Total Waste
Women on Board
Women in Management
Net Zero Target
Employees